August 6, 2020

PPMD Signs Onto Letter Urging Congress to Protect Immunocompromised Patients During the Pandemic

PPMD joined dozens of patient organizations in a letter to Congress urging them to protect immunocompromised patients during the pandemic. Americans living with compromised immune systems have routinely taken precautions in order to avoid becoming…

Learn More

August 4, 2020

ICYMI: Lunch & Learn Sessions

ICYMI: Lunch & Learn Sessions As part of this year’s Virtual Annual Conference, PPMD offered two Lunch & Learn Sessions where we were introduced to family assistance programs available to our community and we took…

Learn More

July 30, 2020

Did You Miss the PPMD Virtual Annual Conference?

Did You Miss the PPMD Virtual Annual Conference? PPMD’s first Virtual Annual Conference was incredible with nearly 2500 families, care providers, researchers, scientists, and industry partners joining us for four days of informative updates on…

Learn More

July 30, 2020

Join PPMD’s Back-To-School Webinar Series

Join PPMD’s Back-To-School Webinar Series Join us for PPMD’s back-to-school webinar series tackling questions and concerns the community has about both in-person and virtual learning environments. PPMD’s Care Team will be joined by leading experts…

Learn More

July 29, 2020

PPMD Announces Pediatric Certified Duchenne Care Center, Akron Children’s Hospital

Today Parent Project Muscular Dystrophy (PPMD) announced the expansion of our renowned Certified Duchenne Care Center Program (CDCCP) with the certification of the clinic at Akron Children’s Hospital (Akron Children’s) in Akron, Ohio. Rachel Schrader,…

Learn More

July 24, 2020

Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold

Tonight at PPMD’s Virtual Annual Conference, Solid Biosciences shared that their IGNITE DMD Phase I/II clinical trial will remain on clinical hold. They also issued a press release here. During this hold, Solid will continue to…

Learn More

July 24, 2020

Catabasis Shares July 2020 Newsletter

Catabasis Pharmaceuticals has shared the latest edition of their community newsletter, which highlights the value of the North Star Ambulatory Assessment in Duchenne. Click here to download the PDF.

Learn More

July 24, 2020

Vita Therapeutics receives Orphan Drug Designation from FDA

Vita Therapeutics, Inc. recently announced that it received orphan drug designation from the FDA for VTA-110, a novel regenerative therapy for the treatment of Duchenne. VTA-110, is a potential first-in-class allogenic iPSC-based therapy that has…

Learn More

July 24, 2020

Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy

PPMD was excited to learn at yesterday’s Virtual Annual Conference that Sarepta Therapeutics was granted Fast Track designation for SRP-9001 by the FDA. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding…

Learn More

July 19, 2020

Check out the schedule for PPMD’s Virtual Conference!

There’s still time to register for PPMD’s Virtual Conference! Though we can’t connect in person this year, there was no way PPMD could let the summer go without hosting our Annual Conference. So this week,…

Learn More